4-((3-Chloropyrazin-2-yl)methyl)-1-isopropylazepane

Catalog No.: 
ACFYEP337
CAS No.: 
1361112-39-1
Molecular Formula: 
C14H22ClN3
Molecular Weight: 
267.80
4-((3-Chloropyrazin-2-yl)methyl)-1-isopropylazepane structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$544.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-((3-Chloropyrazin-2-yl)methyl)-1-isopropylazepane
IUPAC Name4-((3-chloropyrazin-2-yl)methyl)-1-isopropylazepane
MDL No.MFCD21605785
Molecular FormulaC14H22ClN3
Molecular Weight267.80
SMILESCC(N1CCC(CC2=NC=CN=C2Cl)CCC1)C
InChI KeyIDBDUZCSPKGXML-UHFFFAOYSA-N
Synonym4-(3-Chloro-pyrazin-2-ylmethyl)-1-isopropyl-azepane;1H-Azepine, 4-[(3-chloro-2-pyrazinyl)methyl]hexahydro-1-(1-methylethyl)-
CAS No.1361112-39-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACFYEP337 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFYEP337 route product structure diagram
    ACFYEP3371361112-39-1
Inquiry

2. ACFYEP337 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFYEP337 route product structure diagram
    ACFYEP3371361112-39-1
Inquiry

3. ACFYEP337 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFYEP337 route product structure diagram
    ACFYEP3371361112-39-1
Inquiry

Comments (0)